HUMA logo

HUMA
Humacyte Inc

8,208
Mkt Cap
$284.18M
Volume
5.14M
52W High
$2.93
52W Low
$0.5469
PE Ratio
-2.23
HUMA Fundamentals
Price
$1.31
Prev Close
$1.28
Open
$1.28
50D MA
$0.8297
Beta
2.26
Avg. Volume
4.66M
EPS (Annual)
-$0.2582
P/B
24.45
Rev/Employee
$11,076.09
$166.12
Loading...
Loading...
News
all
press releases
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
Here is how Agilon Health (AGL) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.
Zacks
News Placeholder
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization...
Yahoo! Finance: News
News Placeholder
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
News Placeholder
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +10.00% and -59.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) closed at $1.06 in the latest trading session, marking a -1.85% move from the prior day.
Zacks
News Placeholder
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Humacyte, Inc...
Business Wire
News Placeholder
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +16.67% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available